The KCTD9 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human cervical squamous cell carcinoma line Ca Ski, featuring targeted disruption of the KCTD9 gene. This polyclonal model comprises a heterogeneous mixture of edited cells, each carrying distinct CRISPR/Cas9-induced mutations at the KCTD9 locus, collectively resulting in loss-of-function effects across the population. The product enables loss-of-function studies of KCTD9 without the clonal selection biases inherent in single-cell-derived knockouts, preserving broader biological variability. By eliminating KCTD9 expression, this system provides a reliable tool to dissect the gene’s role in ubiquitin-mediated regulation within an HPV-positive cervical cancer context.
The host Ca Ski cell line was originally established from a cervical epidermoid carcinoma metastasis to the mesentery and is widely utilized as a model of HPV-16 positive cervical carcinoma. These adherent epithelial cells stably express the E6 and E7 oncoproteins of human papillomavirus type 16, which are critical drivers of cervical carcinogenesis through inactivation of tumor suppressors p53 and Rb, respectively. Ca Ski cells exhibit key features of aggressive cervical cancer, including deregulated proliferation and apoptosis resistance, making them a clinically relevant platform for investigating tumor biology and evaluating therapeutic interventions. Their HPV-positive status offers a unique opportunity to study how viral oncoproteins interface with host cellular pathways, including the ubiquitin-proteasome system.
KCTD9 encodes a substrate-specific adapter for the cullin-3 (CUL3)-based E3 ubiquitin ligase complex, which catalyzes the transfer of ubiquitin onto specific target proteins destined for proteasomal degradation. As a member of the potassium channel tetramerization domain-containing (KCTD) family, KCTD9 directly interacts with CUL3 and the RING-box protein 1 (RBX1) to recruit unknown substrates for ubiquitination via E2 ubiquitin-conjugating enzymes. Mechanistically, KCTD9 is thought to mediate ubiquitin-dependent regulation of proteins involved in apoptotic signaling and natural killer cell-mediated cytotoxicity, linking it to cell growth control and immune function. Downstream targets remain poorly characterized but may include components of the BCL2 family and caspases, positioning KCTD9 at a regulatory node where ubiquitin signaling intersects with cell survival and immune modulation pathways.
In the Ca Ski cellular environment driven by HPV-16 E6/E7 oncoproteins, KCTD9 knockout is expected to disrupt CUL3-mediated ubiquitination events normally constraining oncogenic processes. Given E6 hijacks E3 ligase complexes to degrade p53, loss of KCTD9 may perturb proteasomal degradation, affecting proliferation, apoptosis, and immune evasion. This model enables investigation of how a host ubiquitin adaptor supports HPV-transformed cell fitness, revealing therapeutic vulnerabilities.
Researchers can employ this polyclonal knockout population in a range of functional assays, including Western blotting and RT-qPCR for KCTD9 ablation, proliferation and apoptosis assays for phenotypic readouts, and ubiquitination or proteasome activity assays to monitor CUL3 pathway integrity. Co-immunoprecipitation with CUL3 validates complex disruption, while flow cytometry and drug sensitivity assays assess cell cycle effects and treatment response. These applications support studies of HPV-positive cervical cancer biology, target validation for ubiquitin pathway drugs, and investigations of drug resistance and immune evasion. For further technical information or customer support, please contact Ascent Research.
